Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

RPRM (reprimo, TP53 dependent G2 arrest mediator candidate)

Written2011-11Alejandro H Corvalan, Veronica A Torres
Laboratory of Molecular Pathology, Epidemiology, Department of Hemathology - Oncology, School of Medicine - P Universidad Catolica de Chile, 391 Marcoleta St - Santiago 8330074 Chile

(Note : for Links provided by Atlas : click)


Alias (NCBI)FLJ90327
HGNC Alias symbFLJ90327
HGNC Alias namecandidate mediator of the p53 dependent G2 arrest
HGNC Previous namereprimo, TP53 dependant G2 arrest mediator candidate
 reprimo, TP53 dependent G2 arrest mediator candidate
LocusID (NCBI) 56475
Atlas_Id 42082
Location 2q23.3  [Link to chromosome band 2q23]
Location_base_pair Starts at 153477338 and ends at 153478762 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping RPRM.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
TNS1 (2q35)::RPRM (2q23.3)


Description Reprimo gene consists of 1 exon. The gene spans 1,47 kb of genomic DNA on the chromosome 2 in the minus strand.
Transcription The mRNA is 1496 bp in length.


Description The open reading frame encodes a 109 amino acid protein with an estimated molecular weight of 11774 Da. Reprimo is a highly glycosylated protein which has two sites in amino acids 7 and 18. The protein has a potential transmembrane site covering amino acids 56 to 76.
Expression The expression of Reprimo is induced by tumor protein p53 following X-ray irradiation.
Localisation When Reprimo is ectopically expressed, it is localized in the cytoplasm.
Function Reprimo is a candidate tumor suppresor gene involved in the G2/M phase cell cycle arrest mediated by tumor protein p53. Reprimo induces cell cycle arrest by inhibiting the nuclear translocation of the Cdc2-Cyclin B1 complex.

Implicated in

Entity Various cancers
Note The aberrant methylation of the promoter region of Reprimo is a common event that may contribute to the pathogenesis of some types of human cancer. Promoter methylation of Reprimo was found in pancreatic cancer (91%), gastric cancer (90%), gallbladder cancer (62%), lymphomas (57%), colorectal cancer (56%) and esophageal adenocarcinomas (40%). In breast cancer, leukemias and lung cancer, promoter methylation of Reprimo was found in less than 40% of tested cases.
Entity Gastric cancer
Disease Aberrant hypermethylation of Reprimo is frequently found in primary gastric cancer as well as in pair plasma samples. In plasma from asymptomatic controls, Reprimo is infrequently methylated. Therefore, plasmatic detection of Reprimo is a putative biomarker for early detection of gastric cancer.
The above histogram represents the percentage of positive cases for Reprimo and other genes (APC, SHP1, CDH-1, ER, SEMA3B and 3OST2) in 43 prospectively collected gastric cancer cases and 31 asymptomatic age- and gender-matched controls. Only Reprimo shows a significant difference in plasma between gastric cancer and asymptomatic controls (Bernal et al., Clin Cancer Res. 2008;14:6264-9).
Entity Pancreatic cancer
Disease Aberrant hypermethylation of Reprimo is also common in pancreatic cell lines (91%) and in pancreatic adenocarcinomas (66%). Reprimo methylation is correlated with poor prognosis in a large series of resected pancreatic cancers. This fact raises the possibility that aberrant methylation of Reprimo is an epigenetic event that may have a mechanistic role in pancreatic cancer.


Reprimo as a potential biomarker for early detection in gastric cancer.
Bernal C, Aguayo F, Villarroel C, Vargas M, Diaz I, Ossandon FJ, Santibanez E, Palma M, Aravena E, Barrientos C, Corvalan AH.
Clin Cancer Res. 2008 Oct 1;14(19):6264-9.
PMID 18829507
Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
Hamilton JP, Sato F, Jin Z, Greenwald BD, Ito T, Mori Y, Paun BC, Kan T, Cheng Y, Wang S, Yang J, Abraham JM, Meltzer SJ.
Clin Cancer Res. 2006 Nov 15;12(22):6637-42.
PMID 17121882
Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase.
Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, Taniguchi T.
J Biol Chem. 2000 Jul 28;275(30):22627-30.
PMID 10930422
Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sato N, Fukushima N, Matsubayashi H, Iacobuzio-Donahue CA, Yeo CJ, Goggins M.
Cancer. 2006 Jul 15;107(2):251-7.
PMID 16752411
Aberrant methylation of Reprimo in lung cancer.
Suzuki M, Shigematsu H, Takahashi T, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Gazdar AF.
Lung Cancer. 2005 Mar;47(3):309-14.
PMID 15713514
Aberrant methylation of Reprimo in human malignancies.
Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba II, Meltzer SJ, Gazdar AF.
Int J Cancer. 2005 Jul 1;115(4):503-10.
PMID 15700311


This paper should be referenced as such :
Corvalan, AH ; TorresVA
RPRM (reprimo, TP53 dependent G2 arrest mediator candidate)
Atlas Genet Cytogenet Oncol Haematol. 2012;16(3):223-224.
Free journal version : [ pdf ]   [ DOI ]

External links


HGNC (Hugo)RPRM   24201
Atlas Explorer : (Salamanque)RPRM
Entrez_Gene (NCBI)RPRM    reprimo, TP53 dependent G2 arrest mediator homolog
GeneCards (Weizmann)RPRM
Ensembl hg19 (Hinxton)ENSG00000177519 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000177519 [Gene_View]  ENSG00000177519 [Sequence]  chr2:153477338-153478762 [Contig_View]  RPRM [Vega]
ICGC DataPortalENSG00000177519
Genatlas (Paris)RPRM
SOURCE (Princeton)RPRM
Genetics Home Reference (NIH)RPRM
Genomic and cartography
GoldenPath hg38 (UCSC)RPRM  -     chr2:153477338-153478762 -  2q23.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)RPRM  -     2q23.3   [Description]    (hg19-Feb_2009)
GoldenPathRPRM - 2q23.3 [CytoView hg19]  RPRM - 2q23.3 [CytoView hg38]
Genome Data Viewer NCBIRPRM [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AA452090 AB043585 AK074808 AK311958 BC002908
RefSeq transcript (Entrez)NM_019845
Consensus coding sequences : CCDS (NCBI)RPRM
Gene ExpressionRPRM [ NCBI-GEO ]   RPRM [ EBI - ARRAY_EXPRESS ]   RPRM [ SEEK ]   RPRM [ MEM ]
Gene Expression Viewer (FireBrowse)RPRM [ Firebrowse - Broad ]
GenevisibleExpression of RPRM in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)56475
GTEX Portal (Tissue expression)RPRM
Human Protein AtlasENSG00000177519-RPRM [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9NS64   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9NS64  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9NS64
Domains : Interpro (EBI)Reprimo    Reprimo_fam   
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)RPRM
AlphaFold pdb e-kbQ9NS64   
Human Protein Atlas [tissue]ENSG00000177519-RPRM [tissue]
Protein Interaction databases
IntAct (EBI)Q9NS64
Ontologies - Pathways
Ontology : AmiGOprotein binding  cytoplasm  regulation of mitotic cell cycle  integral component of membrane  regulation of cell cycle  
Ontology : EGO-EBIprotein binding  cytoplasm  regulation of mitotic cell cycle  integral component of membrane  regulation of cell cycle  
NDEx NetworkRPRM
Atlas of Cancer Signalling NetworkRPRM
Wikipedia pathwaysRPRM
Orthology - Evolution
GeneTree (enSembl)ENSG00000177519
Phylogenetic Trees/Animal Genes : TreeFamRPRM
Homologs : HomoloGeneRPRM
Homology/Alignments : Family Browser (UCSC)RPRM
Gene fusions - Rearrangements
Fusion : MitelmanTNS1::RPRM [2q35/2q23.3]  
Fusion : FusionHubAXIN1--RPRM   
Fusion : QuiverRPRM
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerRPRM [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)RPRM
Exome Variant ServerRPRM
GNOMAD BrowserENSG00000177519
Varsome BrowserRPRM
ACMGRPRM variants
Genomic Variants (DGV)RPRM [DGVbeta]
DECIPHERRPRM [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisRPRM 
ICGC Data PortalRPRM 
TCGA Data PortalRPRM 
Broad Tumor PortalRPRM
OASIS PortalRPRM [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICRPRM  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DRPRM
Mutations and Diseases : HGMDRPRM
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)RPRM
DoCM (Curated mutations)RPRM
CIViC (Clinical Interpretations of Variants in Cancer)RPRM
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry RPRM
NextProtQ9NS64 [Medical]
Target ValidationRPRM
Huge Navigator RPRM [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDRPRM
Pharm GKB GenePA134937494
Clinical trialRPRM
DataMed IndexRPRM
PubMed30 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Jan 20 14:16:40 CET 2022

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us